Image Sourced ShutterStock
Market Herald logo


Be the first with the news that moves the market
  • Specialists in nanotechnology, Anteo Diagnostics, are teaming up with Californian Lumos Diagnostics for the second time.
  • Since collaborating previously in 2018, this follow-up project between the two aims to update the effectiveness in analysing food and water contaminations, and even the detection of pregnancy in handheld devices.
  • If successful, this collaboration will mean detection of targeted pathogens in tests will have lessened error and higher effectiveness, meaning, fewer mistakes in your home pregnancy test for example.

Nanotechnology specialists Anteo Diagnostics announced the collaboration with American company Lumos Diagnostics.

Anteo will combine its Life Sciences division with the Californian diagnostics company to develop a new high-sensitivity, lateral flow biomarker device.

Put simply, this device will assist in new analytical breakthroughs on detecting the presence or absence of targeted pathogens. This is used in food and water contamination or even a handheld pregnancy test.

Anteo Executive Director Christopher Parker says Lumos is a world leader for this kind of technology and the collaboration is an important project for the customer-base.

“We look forward to showcasing the advantages AnteoBind can bring to the Lumos assay development process and to reporting on the progress of this exciting collaboration in the very near future,” Christopher said.

AnteoBind is the company’s leading product that is able to attach macromolecules to surfaces of materials. This is used as a primer or binder for synthetic polymers, functional for use in blood and tissue analysis, and numerous medical devices.

This isn’t the first time the companies will be working together. Previously, the two collaborated on an award-winning handheld device under the joint ‘Medical Countermeasures Program’ (MCM).

Awarded the 2018 National Innovation Award from the International Land Forces Exposition, the field-deployable MCM diagnostic tool assists in protecting the Australian Defence Force from chemical, biological and radiological threats.

“We are pleased to have this opportunity to collaborate again with a familiar and trusted partner on this challenging lateral flow test development. We look forward to working with Anteo on this project,” Lumos CEO, Sacha Dopheide on today’s announcement.

Share prices in ADO have boosted 7.14 per cent this morning in the share market, for a price of 1.5 cents. Anteo’s market cap is sitting at $20.88 million.

ADO by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.